Study guide

Section 13.4: Public Health Laws (HIPAA, OBRA-90, DSCSA Drug Track and Trace)

Texas MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacy Law Foundations & Regulators

Section 1.1: State and Federal Regulatory Bodies Section 1.2: Structure of Texas Pharmacy Law Section 1.3: TSBP Powers and Administrative Procedures Section 1.4: Inspections, Investigations, and Discipline

2 Chapter 2: Pharmacist Licensure & Continuing Education

Section 2.1: Initial Pharmacist Licensure & Reciprocity Section 2.2: License Renewal & Continuing Education Requirements Section 2.3: Inactive Status, Reinstatement, and Administrative Changes Section 2.4: Impaired Pharmacists & Peer Review Programs

3 Chapter 3: Pharmacy Personnel & Supervision Ratios

Section 3.1: Pharmacist-in-Charge (PIC) Responsibilities and Duties Section 3.2: Pharmacy Technicians and Technician Trainees Section 3.3: Pharmacist-to-Technician Supervision Ratios Section 3.4: Duties of Supportive Personnel

4 Chapter 4: Pharmacy Permits & Facility Classifications

Section 4.1: Texas Pharmacy Permit Classes Section 4.2: Class A (Community) Operations & Facilities Section 4.3: Class C (Institutional/Hospital) Operations & Facilities Section 4.4: Central Processing (Class G) and Non-Resident (Class E)

5 Chapter 5: Prescribers & Prescription Validity

Section 5.1: Texas Prescriptive Authority Section 5.2: General Prescription Requirements Section 5.3: Out-of-State and Canadian/Mexican Prescriptions Section 5.4: Self-Prescribing & Prescribing for Family Members

6 Chapter 6: Controlled Substances Schedules & Registration

Section 6.1: Federal vs. Texas Controlled Substances Schedules Section 6.2: DEA Registration & Texas Controlled Substances Act Section 6.3: Scheduled Listed Chemical Products Section 6.4: Controlled Substance Theft or Loss Reporting

7 Chapter 7: Controlled Substances Prescriptions & Dispensing

Section 7.1: CII Prescription Requirements and Validity Section 7.2: CII Refills, Partial Fills, and Emergency Oral Dispensing Section 7.3: CIII-CV Prescription Requirements, Validity, Refills, and Partial Fills Section 7.4: Opioid 10-day Initial Supply Limit & PMP Mandatory Queries

8 Chapter 8: Prescription Monitoring Program (PMP) & Drug Abuse

Section 8.1: Texas Prescription Monitoring Program Reporting & Database Section 8.2: Naloxone Access and Standing Orders in Texas Section 8.3: Corresponding Responsibility & Red Flags of Diversion Section 8.4: Treatment of Substance Use Disorders

9 Chapter 9: Dispensing Standards & Generic Substitution

Section 9.1: Texas Generic Substitution Law Section 9.2: Patient Counseling and Drug Utilization Review Requirements Section 9.3: Prescription Labeling Requirements in Texas Section 9.4: Poison Prevention Packaging Act & Child-Resistant Containers

10 Chapter 10: Prescription Refills, Transfers & Emergency Dispensing

Section 10.1: Prescription Refill Refusal & Professional Judgment Section 10.2: Prescription Transfer Rules Section 10.3: Emergency Refills (72-hour rule & 30-day natural disaster rule) Section 10.4: Return and Reuse of Prescription Medications

11 Chapter 11: Pharmacy Operations, Security & Recordkeeping

Section 11.1: Pharmacy Security, Alarms & Delivery of Drugs in Texas Section 11.2: General Recordkeeping & Document Retention Requirements Section 11.3: Controlled Substance Inventories Section 11.4: Disposal and Destruction of Controlled Substances

12 Chapter 12: Compounding Standards (Sterile & Non-Sterile)

Section 12.1: Non-Sterile Compounding Regulations Section 12.2: Sterile Compounding Regulations Section 12.3: Hazardous Drug Handling Section 12.4: Compounding Recordkeeping & Quality Control

13 Chapter 13: Specialized Pharmacy Practice & Public Safety

Section 13.1: Collaborative Practice Agreements & Drug Therapy Management Section 13.2: Pharmacist Immunization Authority & Protocol Requirements Section 13.3: Automated Dispensing Devices (Class A, C, and remote sites) Section 13.4: Public Health Laws (HIPAA, OBRA-90, DSCSA Drug Track and Trace)

Section 13.4: Public Health Laws (HIPAA, OBRA-90, DSCSA Drug Track and Trace)

Key Takeaways Explain This Topic AI

Under the Texas Medical Records Privacy Act, data breaches affecting 250 or more Texas residents must be reported to the Texas Attorney General within 30 days.

Patient counseling is mandatory in Texas for all new prescriptions; verbal counseling must be provided in person, and a written offer with a toll-free number is required for deliveries.

The Drug Supply Chain Security Act (DSCSA) requires pharmacies to capture and maintain product tracing documents (transaction information and transaction statements) for a minimum of 6 years.

If a pharmacy identifies a product as illegitimate under the DSCSA, it must quarantine the product and notify the FDA via Form 3911 within 24 hours.

HIPAA privacy records, including documented acknowledgments of the Notice of Privacy Practices, must be retained by the pharmacy for 6 years.

Last updated: November 2026

Public Health Laws: HIPAA, OBRA-90, and the DSCSA

Pharmacies operate at the intersection of state jurisprudence and federal public health laws. Three major regulatory frameworks dictate daily operations regarding patient privacy, clinical communication, and drug supply chain integrity: the Health Insurance Portability and Accountability Act (HIPAA), the Omnibus Budget Reconciliation Act of 1990 (OBRA-90), and the Drug Supply Chain Security Act (DSCSA). In many instances, Texas state law imposes requirements that are stricter than these federal baselines.

HIPAA & the Texas Medical Records Privacy Act

While federal HIPAA regulations establish national standards for protecting Protected Health Information (PHI), pharmacists practicing in Texas must comply with the Texas Medical Records Privacy Act (TMRPA) , codified in Chapter 181 of the Texas Health and Safety Code. The TMRPA is significantly broader and stricter than HIPAA in several key areas.

Broader Scope of "Covered Entity"

Under federal HIPAA, a covered entity is generally restricted to healthcare providers, health plans, and healthcare clearinghouses that conduct electronic transactions. Under the Texas TMRPA, a "covered entity" is defined as any person or organization that assembles, collects, analyzes, uses, evaluates, stores, or transmits PHI for commercial, financial, or professional reasons. This includes IT providers, lawyers, and business associates, regardless of whether they transmit transactions electronically.

Strict Employee Training Timeline

Texas law requires that all employees of a covered entity must receive documented training regarding state and federal laws governing PHI. This training must be completed within 60 days of hire (or within 60 days of a change in job duties that involves handling PHI). This is a precise timeline not specified under federal HIPAA, which only requires training within a "reasonable period."

Breach Notification Timeframes

If a pharmacy experiences a breach of unsecured PHI, both federal and state reporting requirements are triggered. Under the TMRPA, if a breach affects 250 or more Texas residents , the pharmacy must notify the Texas Attorney General via their electronic portal as soon as practicable and no later than 30 days after determining the breach occurred. This is a much tighter timeline than the federal HIPAA Breach Notification Rule, which allows up to 60 days to notify the Department of Health and Human Services (HHS). Patients must be notified of a breach within 60 days under both laws.

Record Retention

Under HIPAA, pharmacies must document compliance activities (such as signed Notice of Privacy Practices acknowledgments, privacy officer designations, and training logs) and retain these records for a minimum of 6 years from the date of creation or the date when it was last in effect.

OBRA-90 & Texas Patient Counseling Mandates

The federal Omnibus Budget Reconciliation Act of 1990 (OBRA-90) mandated that states establish standards for prospective Drug Utilization Review (DUR) and patient counseling for Medicaid recipients. Texas expanded these requirements to cover all patients receiving prescriptions, regardless of insurance status.

Prospective Drug Utilization Review

Prior to dispensing any prescription, a Texas pharmacist must review the patient's record to identify potential clinical issues, including:

Therapeutic duplication.

Drug-disease contraindications.

Drug-drug interactions.

Incorrect drug dosage or duration of treatment.

Drug-allergy interactions.

Clinical abuse or misuse.

Mandatory Counseling on New Prescriptions

In Texas, patient counseling is mandatory for all new prescriptions . The pharmacist must initiate the counseling.

In-Person Pickups: If the patient or their agent picks up a new prescription in person, the pharmacist must provide verbal, face-to-face counseling. The pharmacist must discuss clinical aspects of the drug, including administration, side effects, storage, and refill information. Providing a written leaflet or sheet does not satisfy this requirement.

Mailed or Delivered Prescriptions: If the prescription is delivered or mailed to the patient's home, the pharmacy must include a written offer to counsel . This written notice must prominently display a toll-free telephone number that allows the patient to contact a pharmacist for counseling during the pharmacy's normal business hours.

Who Can Counsel: Only a licensed pharmacist or a pharmacist intern under the direct supervision of a pharmacist can perform counseling or clinical patient assessments. Pharmacy technicians may perform cashier and administrative duties but cannot perform counseling, nor can they initiate the counseling process by asking "do you have questions?" instead of having the pharmacist present.

Refusal of Counseling: A patient has the right to refuse counseling. If a patient refuses, the pharmacist must document the refusal in the pharmacy's records. While a pharmacist is not required to force counseling on a refusing patient, the offer to counsel must have been actively initiated by the pharmacy staff.

Drug Supply Chain Security Act (DSCSA)

The DSCSA (codified as Title II of the Drug Quality and Security Act) establishes a national "track-and-trace" system to secure the pharmaceutical supply chain against counterfeit, contaminated, or stolen prescription drugs.

Product Tracing Documents

Pharmacies are prohibited from accepting ownership of prescription drug products unless the seller provides specific product tracing documentation: transaction information and a transaction statement. Older materials call the set the "3 Ts" and include transaction history; FDA says the requirement to provide and receive transaction history effectively ended on November 27, 2023:

Transaction Information (TI): Detailed information about the product, including drug name, strength, dosage form, NDC, container size, number of containers, transaction date, shipment date, and the names/addresses of the transferor and transferee.

Transaction History (TH) (no longer required): A paper or electronic record that outlined the transaction information for each prior transfer of the product, starting from the original manufacturer.

Transaction Statement (TS): A statement by the entity transferring the product confirming compliance with the DSCSA (e.g., that they are an authorized partner, received the product from an authorized partner, and did not knowingly ship suspect or illegitimate products).

Recordkeeping under DSCSA

Pharmacies must maintain the TI and TS for each prescription drug product received for a minimum of 6 years from the date of the transaction. These records can be kept electronically.

Suspect vs. Illegitimate Products

Suspect Product: A product that a pharmacy has reason to believe is counterfeit, diverted, stolen, intentionally adulterated, or otherwise unfit for distribution. If a pharmacy identifies a suspect product, it must quarantine the drug and conduct an investigation to verify its legitimacy.

Illegitimate Product: A product where there is confirmed evidence that it is counterfeit, diverted, stolen, or unfit. If a product is determined to be illegitimate, the pharmacy must notify the FDA using Form FDA 3911 and notify all immediate trading partners within 24 hours of making the determination.

Exam Traps and Legal Nuances

Warning

Breach Notification Timelines: On the MPJE, look closely at who is being notified and the number of residents affected. For a breach affecting 250+ Texas residents, notice to the Texas AG is due within 30 days . Notice to patients is due within 60 days . Many candidates lose points by selecting 60 days for both.

Caution

Counseling Delegation: A common question involves a pharmacy technician handing a new prescription to a patient and asking, "Do you have any questions for the pharmacist today?" In Texas, this is illegal . The pharmacist must initiate the counseling process verbally for in-person pickups.